[Molecular pathological identification of predictive biomarkers: a new task for diagnostic pathology].
The clinical management of cancer patients is still based to a great extent on the histological staging, grading, and tumor typing performed by the pathologist. As a result part of the patients are subjected to unnecessary treatment regimens with high rates of side effects and no advantages while another part of the patients could benefit from (adjuvant) therapies they would not routinely receive based on their tumor staging/grading. This situation has led to a search for so-called predictive biomarkers, which would allow better assessment of the clinical course, probability of metastases, and the efficacy of the treatment method, thus making it possible to individualize treatment for each cancer patient.
Institut für Pathologie und Neuropathologie, Universitätsklinikum Essen, Universität Duisburg-Essen, Hufelandstrasse 55, 45134 Essen, Deutschland. kw.schmid@uk-essen.de
K W
KW
Schmid
D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D020869:Gene Expression Profiling; D006801:Humans; D009363:Neoplasm Proteins / Q000235:genetics*; D009367:Neoplasm Staging; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D040901:Proteomics; D016896:Treatment Outcome; D014571:Urologic Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000628:therapy
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins